東北製藥(000597.SZ):方大鋼鐵要約收購期滿、共接獲2.77萬股有效接納 明起復牌
格隆匯9月27日丨東北製藥(000597.SZ)公佈,公司於2021年8月23日披露了《東北製藥集團股份有限公司要約收購報吿書》,方大鋼鐵因受讓東藥集團及其一致行動人盛京金控集團所持公司全部股份(轉讓的股份數量約為2.55億股,佔公司總股本的18.91%)而觸發法定全面要約收購義務,向公司除方大鋼鐵及其一致行動人、東藥集團、盛京金控集團以外的其他股東發出全面要約收購。要約收購價格為4.93元/股。
該次要約收購期限共計30個自然日,要約收購期限自2021年8月24日起至2021年9月22日止。截至該公吿披露日,該次要約收購事項已經實施完畢。根據中國證券登記結算有限責任公司深圳分公司提供的數據統計,2021年8月24日至2021年9月22日要約收購期間,最終有11個賬户共計約2.77萬股股份接受收購人發出的要約。該要約收購股份的過户手續已於2021年9月27日辦理完成。
該次要約收購完成後,方大鋼鐵持有公司約1.88億股股份,佔公司總股本的13.98%;此次要約收購完成後,方大鋼鐵及其一致行動人合計持有公司約5.25億股股份,佔公司總股本的38.97%。
此外,公司將於9月28日開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.